2023 North America Conference on Lung Cancer (NACLC) - Posters and Abstracts-PP01.90 (Poster) Real-world demographics, clinical characteristics, treatment patterns and clinical outcomes for US patients with limited-stage small-cell lung cancer

PP01.90 (Poster) Real-world demographics, clinical characteristics, treatment patterns and clinical outcomes for US patients with limited-stage small-cell lung cancer

Back to course

Pdf Summary

This study aimed to assess the real-world clinical characteristics, treatment patterns, and outcomes of patients with newly diagnosed limited-stage small-cell lung cancer (LS-SCLC) in the United States. The findings were consistent with the known epidemiology of LS-SCLC. The majority of patients were diagnosed with stage III SCLC and received chemoradiotherapy (CRT), in line with treatment guidelines. However, some patients did not receive the standard of care. Less than half of patients who received curative-intent treatment received prophylactic cranial irradiation (PCI). Surgery was associated with the longest overall survival (OS), reflecting the early disease stage of these patients, while patients receiving chemotherapy alone had the worst outcomes. These results highlight the need for new therapeutic strategies for the treatment of LS-SCLC.<br /><br />The study analyzed data from 1552 patients with LS-SCLC. The demographic and baseline characteristics of the patients were largely as expected, with a median age of 67 and a majority of white and female patients. The median OS for all patients was 20.3 months, and the 5-year OS rate was 21.7%. Patients with more advanced disease had shorter OS. Patients who had surgery had the longest median OS, while patients who received chemotherapy only had the shortest median OS. The use of PCI was associated with longer OS, but only a minority of patients received it.<br /><br />The study was conducted using data from a large US database and provided insights into real-world treatment patterns for LS-SCLC. The findings highlight the limited benefit of current treatment approaches, especially in patients with more advanced disease, and emphasize the need for new therapies to improve outcomes. The study was sponsored by AstraZeneca and the authors disclosed conflicts of interest related to the company.

Asset Subtitle

Anne Chiang

Keywords

limited-stage small-cell lung cancer

clinical characteristics

treatment patterns

outcomes

chemoradiotherapy

prophylactic cranial irradiation

surgery

overall survival

chemotherapy

therapeutic strategies